148 related articles for article (PubMed ID: 38681137)
1. Extreme hypofractionated stereotactic radiotherapy for localized prostate Cancer: Efficacy and late urinary toxicity according to transurethral resection of the prostate history.
Galienne M; Risbourg S; Lacornerie T; Taillez A; Lartigau E; Barthoulot M; Pasquier D
Clin Transl Radiat Oncol; 2024 May; 46():100779. PubMed ID: 38681137
[TBL] [Abstract][Full Text] [Related]
2. Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP).
Pepin A; Aghdam N; Shah S; Kataria S; Tsou H; Datta S; Danner M; Ayoob M; Yung T; Lei S; Gurka M; Collins BT; Krishnan P; Suy S; Hankins R; Lynch JH; Collins SP
Front Oncol; 2020; 10():555. PubMed ID: 32432033
[No Abstract] [Full Text] [Related]
3. Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity.
Franzese C; Badalamenti M; Di Brina L; D'Agostino G; Franceschini D; Comito T; Clerici E; Navarria P; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
Strahlenther Onkol; 2020 Jul; 196(7):608-616. PubMed ID: 32303782
[TBL] [Abstract][Full Text] [Related]
4. Surgical Treatments of Benign Prostatic Hyperplasia and Prostate Cancer Stereotactic Radiotherapy: Impact on Long-Term Genitourinary Toxicity.
Huck C; Achard V; Zilli T
Clin Oncol (R Coll Radiol); 2022 Sep; 34(9):e392-e399. PubMed ID: 35715340
[TBL] [Abstract][Full Text] [Related]
5. Genitourinary toxicity in patients receiving TURP prior to hypofractionated radiotherapy for clinically localized prostate cancer: A scoping review.
Neerhut T; Grills R; Lynch R; Preece PD; McLeod K
Urol Oncol; 2024 Jun; 42(6):165-174. PubMed ID: 38503591
[TBL] [Abstract][Full Text] [Related]
6. The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancer.
Lin YW; Lin LC; Lin KL
Front Oncol; 2014; 4():278. PubMed ID: 25401085
[TBL] [Abstract][Full Text] [Related]
7. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients.
Nicosia L; Mazzola R; Rigo M; Figlia V; Giaj-Levra N; Napoli G; Ricchetti F; Corradini S; Ruggieri R; Alongi F
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2547-2554. PubMed ID: 31324979
[TBL] [Abstract][Full Text] [Related]
8. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy.
Bolzicco G; Favretto MS; Satariano N; Scremin E; Tambone C; Tasca A
BMC Urol; 2013 Oct; 13():49. PubMed ID: 24134138
[TBL] [Abstract][Full Text] [Related]
9. Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial.
Hannoun-Levi JM; Chand-Fouche ME; Pace-Loscos T; Gautier M; Gal J; Schiappa R; Pujol N
Clin Transl Radiat Oncol; 2022 Nov; 37():64-70. PubMed ID: 36093342
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma.
Kim HJ; Phak JH; Kim WC
Radiat Oncol J; 2016 Dec; 34(4):260-264. PubMed ID: 27306777
[TBL] [Abstract][Full Text] [Related]
11. Long-term urinary toxicity after 3-dimensional conformal radiotherapy for prostate cancer in patients with prior history of transurethral resection.
Sandhu AS; Zelefsky MJ; Lee HJ; Lombardi D; Fuks Z; Leibel SA
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):643-7. PubMed ID: 11020559
[TBL] [Abstract][Full Text] [Related]
12. Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.
Zelefsky MJ; Kollmeier M; McBride S; Varghese M; Mychalczak B; Gewanter R; Garg MK; Happersett L; Goldman DA; Pei I; Lin M; Zhang Z; Cox BW
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):42-49. PubMed ID: 30611838
[TBL] [Abstract][Full Text] [Related]
13. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
[TBL] [Abstract][Full Text] [Related]
15. Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trials.
Glicksman RM; Liu SK; Cheung P; Vesprini D; Chu W; Chung HT; Morton G; Deabreu A; Davidson M; Ravi A; Musunuru HB; Helou J; Ho L; Zhang L; Loblaw A
Radiother Oncol; 2021 Oct; 163():159-164. PubMed ID: 34487764
[TBL] [Abstract][Full Text] [Related]
16. Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
Kole TP; Tong M; Wu B; Lei S; Obayomi-Davies O; Chen LN; Suy S; Dritschilo A; Yorke E; Collins SP
Acta Oncol; 2016; 55(1):52-8. PubMed ID: 25972264
[TBL] [Abstract][Full Text] [Related]
17. Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost.
Phuong C; Chan JW; Ni L; Wall P; Mohamad O; Wong AC; Hsu IC; Chang AJ
Radiat Oncol; 2022 Jan; 17(1):12. PubMed ID: 35057827
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.
Davis J; Sharma S; Shumway R; Perry D; Bydder S; Simpson CK; D'Ambrosio D
Cureus; 2015 Dec; 7(12):e395. PubMed ID: 26798571
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy with CyberKnife
Borzillo V; Scipilliti E; Pezzulla D; Serra M; Ametrano G; Quarto G; Perdonà S; Rossetti S; Pignata S; Crispo A; Di Gennaro P; D'Alesio V; Arrichiello C; Buonanno F; Mercogliano S; Russo A; Tufano A; Di Franco R; Muto P
Front Oncol; 2023; 13():1270498. PubMed ID: 38023175
[TBL] [Abstract][Full Text] [Related]
20. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.
Di Muzio NG; Fodor A; Noris Chiorda B; Broggi S; Mangili P; Valdagni R; Dell'Oca I; Pasetti M; Deantoni CL; Chiara A; Berardi G; Briganti A; Calandrino R; Cozzarini C; Fiorino C
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):490-500. PubMed ID: 26961088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
